

Summary PK Parameters in Subjects Following Single IV Dose(s) of AEB1102 (Part 1)

Dose (mg/kg)	Stat. Param.	ADA Status	T _{1/2} (hr)	T _{max} ¹ (hr)	C _{max} (µg/mL)	AUC ₀₋₄ (hr*µg/mL)	AUC ₀₋₁₆₈ (hr*µg/mL)	AUC _{0-∞} (hr*µg/mL)	CL (mL/hr/kg)	V _{ss} (mL/kg)
0.015	N	ALL	6	16	16	10	6	6	6	6
	Mean		30.5	0.342	0.428	5.77	18.2	18.9	0.959	36.2
	SD		11.8	0.183, 8.28	0.0915	3.21	7.33	8.19	0.499	6.01
	CV%		38.8	NA	21.4	55.6	40.3	43.4	52.0	16.6
	N	Negative	5	14	14	9	5	5	5	5
	Mean		33.5	0.300	0.436	6.15	20.2	21.0	0.776	35.0
	SD		10.3	0.183, 8.28	0.0955	3.16	6.00	6.97	0.245	5.92
	CV%		30.9	NA	21.9	51.4	29.7	33.1	31.6	16.9
	N	Positive/ Impact	1	2	2	1	1	1	1	1
	Mean		15.4	0.792	0.373	2.39	8.00	8.00	1.87	42.0
	SD		NR	0.383, 1.20	NR	NR	NR	NR	NR	NR
	CV%		NR	NA	NR	NR	NR	NR	NR	NR
0.03*	N	ALL	8	14	14	8	8	8	8	8
	Mean		21.0	0.884	0.723	17.4	26.5	26.9	1.57	36.0
	SD		9.47	0.217, 4.28	0.247	10.9	14.6	14.9	1.01	5.98
	CV%		45.0	NA	34.1	62.6	54.9	55.5	64.3	16.6
	N	Negative	4	5	5	4	4	4	4	4
	Mean		29.4	0.583	0.925	26.8	38.6	39.4	0.781	32.8
	SD		1.43	0.217, 4.28	0.207	5.04	7.61	7.83	0.132	5.00
	CV%		4.87	NA	22.4	18.8	19.7	19.9	16.9	15.2
	N	Positive/ Impact	4	8	8	4	4	4	4	4
	Mean		12.7	0.884	0.628	8.02	14.4	14.5	2.36	39.2
	SD		4.73	0.250, 4.12	0.201	4.09	6.70	6.70	0.838	5.55
	CV%		37.2	NA	32.0	51.0	46.5	46.3	35.6	14.1
	N	Positive/ Unknown	0	1	1	0	0	0	0	0
	Mean		ND	3.97	0.476	ND	ND	ND	ND	ND
	SD		ND	3.97, 3.97	NR	ND	ND	ND	ND	ND
	CV%		ND	NR	NR	ND	ND	ND	ND	ND
0.06*	N	ALL	9	11	11	9	9	9	9	9
	Mean		26.7	0.383	1.73	43.5	63.0	64.4	1.27	37.7
	SD		9.50	0.167, 4.20	0.538	19.8	29.1	30.2	0.925	6.79
	CV%		35.5	NA	31.1	45.5	46.2	47.0	73.0	18.0
	N	Negative	6	7	7	6	6	6	6	6
	Mean		31.9	0.433	1.80	53.4	77.8	79.8	0.799	36.2
	SD		3.70	0.217, 4.20	0.349	13.8	20.6	21.5	0.220	8.12
	CV%		11.6	NA	19.4	25.9	26.4	26.9	27.5	22.4
	N	Positive/ No Impact	1	1	1	1	1	1	1	1
	Mean		26.7	0.383	1.74	39.4	54.3	54.9	1.09	41.4
	SD		NR	0.383, 0.383	NR	NR	NR	NR	NR	NR
	CV%		NR	NA	NR	NR	NR	NR	NR	NR
	N	Positive/ Impact	1	1	1	1	1	1	1	1
	Mean		9.31	0.167	2.60	11.4	17.7	17.7	3.39	40.1
	SD		NR	0.167, 0.167	NR	NR	NR	NR	NR	NR
	CV%		NR	NA	NR	NR	NR	NR	NR	NR
	N	Negative/ lingering impact	1	1	1	1	1	1	1	1
	Mean		13.0	0.367	1.53	20.2	28.1	28.1	2.13	40.2
	SD		NR	0.367, 0.367	NR	NR	NR	NR	NR	NR
	CV%		NR	NA	NR	NR	NR	NR	NR	NR
	N	Positive/ Unknown	0	1	1	0	0	0	0	0
	Mean		ND	4.03	0.573	ND	ND	ND	ND	ND
	SD		ND	4.03, 4.03	NR	ND	ND	ND	ND	ND
	CV%		ND	NR	NR	ND	ND	ND	ND	ND
0.1*	N	ALL	2	4	4	2	2	2	2	2
	Mean		30.5	0.667	2.27	53.0	77.3	79.8	1.33	52.1
	SD		NR	0.233, 4.02	0.238	NR	NR	NR	NR	NR
	CV%		NR	NA	10.5	NR	NR	NR	NR	NR
	N	Negative	2	3	3	2	2	2	2	2
	Mean		30.5	0.283	2.35	53.0	77.3	79.8	1.33	52.1
	SD		NR	0.233, 4.02	0.204	NR	NR	NR	NR	NR
	CV%		NR	NA	8.7	NR	NR	NR	NR	NR
	N	Positive/ Unknown	0	1	1	0	0	0	0	0
	Mean		ND	1.05	2.01	ND	ND	ND	ND	ND
	SD		ND	1.05, 1.05	NR	ND	ND	ND	ND	ND
	CV%		ND	NR	NR	ND	ND	ND	ND	ND
0.2	N	ALL/ Negative	1	1	1	1	1	1	1	1
	Mean		32.0	0.567	6.13	235	247	253	0.789	35.3
	SD		NR	0.567, 0.567	NR	NR	NR	NR	NR	NR
	CV%		NR	NA	NR	NR	NR	NR	NR	NR

¹ Median and range (Min, Max) presented;

* There is one patient (per dose cohort) with unknown ADA impact due to insufficient measurable/available concentrations.

NR: not reported;

ND: not determined;

NA: not applicable.